Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,011 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients.
Martín-Carbonero L, Domínguez-Domínguez L, Bailón L, Torres R, Rubio R, Ron R, Moreno F, Rico M, Jimenez-Nacher I, González-García J, Pulido F, Montes ML. Martín-Carbonero L, et al. Among authors: torres r. Enferm Infecc Microbiol Clin (Engl Ed). 2019 Jun-Jul;37(6):367-372. doi: 10.1016/j.eimc.2018.09.013. Epub 2018 Nov 23. Enferm Infecc Microbiol Clin (Engl Ed). 2019. PMID: 30477904 English, Spanish.
[Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].
Cervero M, Torres R, Jusdado JJ, Rodríguez-Rosado R, Del Alamo M, García-Benaya E. Cervero M, et al. Among authors: torres r. Enferm Infecc Microbiol Clin. 2006 Aug-Sep;24(7):426-30. doi: 10.1157/13091779. Enferm Infecc Microbiol Clin. 2006. PMID: 16956530 Spanish.
Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease.
Pulido F, Del Pozo MA, Fernández-Guerrero M, Moreno A, Oteo JA, Flores J, Pedrol E, Torres R, Padilla B, Téllez MJ, García J, González-García J; ESPPE Study Group. Pulido F, et al. Among authors: torres r. HIV Clin Trials. 2008 Mar-Apr;9(2):83-90. doi: 10.1310/hct0902-83. HIV Clin Trials. 2008. PMID: 18474493
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI, Pulido F, Martinez E, Arrizabalaga J, Domingo P, Portilla J, Ocampo A, Muñoz J, Torres R, Arribas JR; GESIDA-6008-KRETA Study Group. Bernardino JI, et al. Among authors: torres r. J Antimicrob Chemother. 2013 Jun;68(6):1373-81. doi: 10.1093/jac/dks540. Epub 2013 Feb 5. J Antimicrob Chemother. 2013. PMID: 23386261 Clinical Trial.
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group. Pulido F, et al. Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734. Clin Infect Dis. 2017. PMID: 29020293 Clinical Trial.
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zárraga MA, Vivancos MJ, Moreno S; Spanish HIV Research Network (CoRIS). Serrano-Villar S, et al. Lancet HIV. 2020 Aug;7(8):e565-e573. doi: 10.1016/S2352-3018(20)30202-2. Lancet HIV. 2020. PMID: 32763219 Clinical Trial.
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017).
Beltrán-Pavez C, Gutiérrez-López M, Rubio-Garrido M, Valadés-Alcaraz A, Prieto L, Ramos JT, Jiménez De Ory S, Navarro M, Díez-Romero C, Pulido F, Valencia E, Holguín Á; Madrid Cohort of HIV-Infected Children integrated in the Pediatric Branch of the Spanish National AIDS Network (CoRISpe). Beltrán-Pavez C, et al. Sci Rep. 2020 Oct 9;10(1):16891. doi: 10.1038/s41598-020-70861-x. Sci Rep. 2020. PMID: 33037235 Free PMC article.
2,011 results